Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LDHA | P00338 | 2/20 | 0.57 |
| ▸ | FPR2 | P25090 | 3/20 | 0.46 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.45 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.45 |
| ▸ | TPMT | P51580 | 1/20 | 0.44 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.44 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | ALB | P02768 | 1/20 | 0.42 |
| ▸ | ESR1 | P03372 | 1/20 | 0.42 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.42 |
| ▸ | RARB | P10826 | 1/20 | 0.42 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.42 |
| ▸ | ADRB3 | P13945 | 1/20 | 0.42 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.42 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.42 |
| ▸ | HTR2A | P28223 | 1/20 | 0.42 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.42 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.42 |
| ▸ | NR1I3 | Q14994 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30877184 | 0.88 | LDHA (0.68) | LDHAMDM2CYP1A2SLC7A5LMNA | |
| SCHEMBL17161259 | 0.83 | KDM6B (0.56) | LDHAFPR2CYP1A2TPMTCYP2D6 | |
| SCHEMBL17518184 | 0.83 | CYP1A2 (0.46) | LDHAFPR2MDM2CYP1A2CYP2D6 | |
| SCHEMBL31649452 | 0.83 | KDM6B (0.56) | LDHAFPR2CYP1A2TPMTCYP2D6 | |
| Iodofalan SCHEMBL44620 | 0.81 | SLC7A5 (0.69) | CYP1A2SLC7A5LMNANFKB1PTGS1 | |
| SCHEMBL457465 | 0.81 | TBXAS1 (0.51) | FPR2CYP1A2CYP2D6LMNAALB | |
| Iodofalan SCHEMBL44619 | 0.81 | SLC7A5 (0.69) | CYP1A2SLC7A5LMNANFKB1PTGS1 | |
| Iodofalan SCHEMBL44618 | 0.81 | SLC7A5 (0.69) | CYP1A2SLC7A5LMNANFKB1PTGS1 | |
| SCHEMBL12639935 | 0.81 | TBXAS1 (0.51) | FPR2CYP1A2CYP2D6LMNAALB | |
| SCHEMBL9910745 | 0.81 | TBXAS1 (0.51) | FPR2CYP1A2CYP2D6LMNAALB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12612421-B2 | Method for producing 4-borono-L-phenylalanine and intermediate thereof | STELLA PHARMA CORPORATION (JP) | 2026-04-28 | — | — | US | disclosed |
| US-20230416280-A1 | METHOD FOR PRODUCING 4-BORONO-L-PHENYLALANINE AND INTERMEDIATE THEREOF | STELLA PHARMA CORPORATION (JP) | 2023-12-28 | — | — | US | disclosed |
| EP-2975022-B1 | NOVEL HYDROXAMIC ACID DERIVATIVE OR SALT THEREOF | FUJIFILM TOYAMA CHEMICAL CO LTD (JP) | 2019-05-08 | — | — | EP | disclosed |
| US-9862676-B2 | Hydroxamic acid derivative or salt thereof | TOYAMA CHEMICAL CO., LTD. (JP) | 2018-01-09 | — | — | US | disclosed |
| US-20160039751-A1 | NOVEL HYDROXAMIC ACID DERIVATIVE OR SALT THEREOF | TOYAMA CHEMICAL CO., LTD. (JP) | 2016-02-11 | — | — | US | disclosed |
| EP-2975022-A1 | NOVEL HYDROXAMIC ACID DERIVATIVE OR SALT THEREOF | Toyama Chemical Co., Ltd. (JP) | 2016-01-20 | — | — | EP | disclosed |
| US-20120309674-A1 | PSEUDODIPEPTIDES AS MMP INHIBITORS | COMMISSARIAT A L'ENERGIE ATOMIQUE ET AUX ENE ALT (FR) | 2012-12-06 | — | — | US | disclosed |
| US-20120309674-A1 | PSEUDODIPEPTIDES AS MMP INHIBITORS | COMMISSARIAT A L'ENERGIE ATOMIQUE ET AUX ENE ALT (FR) | 2012-12-06 | — | — | US | disclosed |
| US-20120309674-A1 | PSEUDODIPEPTIDES AS MMP INHIBITORS | COMMISSARIAT A L'ENERGIE ATOMIQUE ET AUX ENE ALT (FR) | 2012-12-06 | — | — | US | disclosed |
| WO-2011023864-A1 | PSEUDODIPEPTIDES AS MMP INHIBITORS | COMMISSARIAT A L'ENERGIE ATOMIQUE ET AUX ENERGIES ALTERNATIVES (FR) | 2011-03-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230416280-A1 | METHOD FOR PRODUCING 4-BORONO-L-PHENYLALANINE AND INTERMEDIATE THEREOF | PAH, BCAT2, BCAT1 | LDHA 1963/4885FPR2 2193/4885MDM2 3931/4885 |
| US-20160039751-A1 | NOVEL HYDROXAMIC ACID DERIVATIVE OR SALT THEREOF | H1-0, H1-2, HDAC1 | LDHA 162/4885FPR2 1112/4885MDM2 4520/4885 |
| US-12612421-B2 | Method for producing 4-borono-L-phenylalanine and intermediate thereof | BCAT2, BCAT1, CLIC4 | LDHA 338/4885FPR2 1793/4885MDM2 4501/4885 |
| US-20120309674-A1 | PSEUDODIPEPTIDES AS MMP INHIBITORS | MMP3, MMP11, TIMP3 | LDHA 3096/4885FPR2 840/4885MDM2 2634/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.